LY3025876

LY3025876 is a synthetic peptide drug developed by Eli Lilly for the treatment of type 2 diabetes mellitus. It acts as a modulator of fibroblast growth factor 21 (FGF21), a hormone involved in glucose and lipid metabolism. The drug was investigated primarily as an antihyperglycemic agent to improve glycemic control in patients with type 2 diabetes. Clinical development included phase I trials assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with type 2 diabetes. The mechanism of action is believed to involve modulation of FGF21 signaling pathways; however, detailed mechanistic data have not been publicly disclosed[1][3][4][5].